Eli Lilly (LLY) is trading higher as investors price in the FDA approval of Foundayo (orforglipron), a once-daily oral GLP-1 therapy for adults with obesity, or overweight with weight-related medical problems. The approval positions Lilly with a high-convenience alternative to injections, and the start of shipments on April 6, 2026 adds near-term commercialization momentum as prescriptions begin flowing through pharmacies and direct channels.

Foundayo is a small-molecule oral GLP-1 designed to be taken any time of day without food or water restrictions, reducing friction versus earlier oral GLP-1 regimens that require fasting and timing rules. The market is watching whether convenience can expand the addressable population—particularly patients hesitant about injections—while strengthening Lilly’s leadership across obesity and metabolic disease alongside its injectable franchise.

The immediate investor debate centers on uptake speed, formulary access, and out-of-pocket affordability during the ramp. Lilly has communicated broad global filing activity across more than 40 countries and plans to launch shortly after approvals, and the U.S. rollout timing (with shipments beginning April 6) keeps attention on early prescription trends and payer coverage decisions over the next several weeks.

Key swing factors include initial demand signals, supply availability, and how aggressively insurers cover an oral GLP-1 for weight management. Investors will also monitor whether the pill’s real-world persistence and tolerability support durable volume growth and how competitive dynamics evolve as oral options proliferate in obesity care.